

Bardia Nourbakhsh, Mas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5562371/publications.pdf>

Version: 2024-02-01

42
papers

1,415
citations

430874

18
h-index

345221

36
g-index

45
all docs

45
docs citations

45
times ranked

2541
citing authors

#	ARTICLE	IF	CITATIONS
1	Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. <i>JAMA Neurology</i> , 2016, 73, 790.	9.0	177
2	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. <i>Neurology</i> , 2017, 88, 826-831.	1.1	168
3	B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102195.	2.0	123
4	Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation. <i>Journal of Clinical Investigation</i> , 2020, 130, 3467-3482.	8.2	109
5	Neutralization of IL-9 Ameliorates Experimental Autoimmune Encephalomyelitis by Decreasing the Effector T Cell Population. <i>Journal of Immunology</i> , 2010, 185, 4095-4100.	0.8	105
6	Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. <i>Lancet Neurology</i> , The, 2021, 20, 38-48.	10.2	90
7	IL-9 is important for T cell activation and differentiation in autoimmune inflammation of the central nervous system. <i>European Journal of Immunology</i> , 2011, 41, 2197-2206.	2.9	76
8	Dietary salt intake and time to relapse in paediatric multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1350-1353.	1.9	58
9	Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1211-1221.	3.7	55
10	Kit (W-sh) Mice Develop Earlier and More Severe Experimental Autoimmune Encephalomyelitis Due to Absence of Immune Suppression. <i>Journal of Immunology</i> , 2011, 187, 274-282.	0.8	48
11	Multiple Sclerosis Risk Factors and Pathogenesis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 596-610.	0.8	41
12	COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , 2021, 268, 2023-2025.	3.6	39
13	Longitudinal associations between brain structural changes and fatigue in early MS. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 29-33.	2.0	36
14	Salutary Effects of N-Acetylcysteine on Apoptotic Damage in a Rat Model of Testicular Torsion. <i>Urologia Internationalis</i> , 2007, 79, 248-254.	1.3	29
15	Longitudinal associations between MRI and cognitive changes in very early MS. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 47-52.	2.0	28
16	Multi-omic evaluation of metabolic alterations in multiple sclerosis identifies shifts in aromatic amino acid metabolism. <i>Cell Reports Medicine</i> , 2021, 2, 100424.	6.5	26
17	Heterogeneity in association of remote herpesvirus infections and pediatric MS. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1222-1228.	3.7	25
18	Low dose zymosan ameliorates both chronic and relapsing experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 254, 28-38.	2.3	23

#	ARTICLE	IF	CITATIONS
19	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e533.	6.0	18
20	Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 64, 67-76.	1.8	16
21	<scp>Multiple Sclerosis</scp> Is Rare in Epsteinâ€“Barr Virusâ€“Seronegative Children with <scp>Central Nervous System</scp> Inflammatory Demyelination. <i>Annals of Neurology</i> , 2021, 89, 1234-1239.	5.3	16
22	Detection of Neoplasms by Metagenomic Next-Generation Sequencing of Cerebrospinal Fluid. <i>JAMA Neurology</i> , 2021, 78, 1355.	9.0	14
23	Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 366, 229-233.	0.6	13
24	Association Between Glutamate Blockade and Fatigue in Patients With Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1374.	9.0	12
25	Novel MS vital sign: multiâ€“sensor captures upper and lower limb dysfunction. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 288-295.	3.7	8
26	A pilot study of oxidative pathways in MS fatigue: randomized trial of Nâ€“acetyl cysteine. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 811-824.	3.7	8
27	Isoniazid in autoimmunity: a trigger for multiple sclerosis?. <i>Therapeutic Advances in Neurological Disorders</i> , 2014, 7, 253-256.	3.5	7
28	Occipital Headache in Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids (<scp>CLIPPERS</scp>). <i>Headache</i> , 2018, 58, 458-459.	3.9	7
29	Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosisâ€“related fatigue. <i>Multiple Sclerosis Journal</i> , 2021, 27, 942-953.	3.0	7
30	Ethical considerations in the treatment of multiple sclerosis fatigue. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103129.	2.0	7
31	Biosensor vital sign detects multiple sclerosis progression. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 4-14.	3.7	6
32	The Role of Remote Monitoring in Evaluating Fatigue in Multiple Sclerosis: A Review. <i>Frontiers in Neurology</i> , 0, 13, .	2.4	6
33	Homonymous hemianopia as the first sign of posterior cortical atrophy. <i>Journal of the Neurological Sciences</i> , 2017, 373, 38-40.	0.6	5
34	Extensive Involvement of Multiple Cranial and Spinal Nerves in Lymphomatous Meningitis. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 599-600.	0.5	2
35	Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 103-107.	2.0	2
36	Review ofThe Biology of Multiple Sclerosis. <i>JAMA Neurology</i> , 2013, 70, 1461.	9.0	1

#	ARTICLE	IF	CITATIONS
37	Clinical Reasoning: A 16-year-old girl with subacute weakness and sensory loss. <i>Neurology</i> , 2017, 88, e225-e229.	1.1	1
38	Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue. <i>Multiple Sclerosis Journal</i> , 2021, 27, 135245852110423.	3.0	1
39	Clinical Reasoning: Left hemiparesis, ataxia, and optic neuritis in a child previously treated for pineoblastoma. <i>Neurology</i> , 2016, 86, e161-e165.	1.1	0
40	Executive Functioning in Pediatric Multiple Sclerosis: Considering the Impact of Emotional and Psychosocial Factors. <i>Journal of Pediatric Neuropsychology</i> , 2017, 3, 206-217.	0.6	0
41	Extensive Involvement of Multiple Cranial and Spinal Nerves in Lymphomatous Meningitis – ERRATUM. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 627-627.	0.5	0
42	Determining the Etiology of Internuclear Ophthalmoplegia in a Patient with a Cardiac Pacemaker and		